A good hair day for Veradermics Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 27 April, 2026

ASCO is about to deliver some make-or-break cancer data. Join us to figure out which pipeline bets will pay off. Get your spot now.

presented by Glob­al part­ner­ing be­fore the term sheet: de-risk­ing bio­phar­ma deals from day one

SPOTLIGHT In Focus Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapy

news Intellia's in vivo CRISPR therapy first to succeed in Phase 3 Veradermics wins at growing hair with oral Rogaine in late-stage trial Sun Pharma to buy Organon for $11.75B in major portfolio expansion Investment in UK biotechs shows early signs of recovery, report says Exclusive: Fathom raises $47M, blending AI and physics in drug discovery

Apr 28 12:30 pm ET Connection ≠ continuity: Rethinking long-term evidence in the age of tokenization sponsored by PicnicHealth Apr 29 12:00 pm ET From genotype to outcomes: Real-world evidence in glomerular diseases sponsored by Natera May 05 11:00 am ET The path to self-driving: Leveraging agentic AI to drive the future of clinical drug development sponsored by Medable May 12 10:30 am ET Rules of engagement: How G3BP2 paves the way to rationalize novel degrons sponsored by Thermo Fisher May 20 11:00 am ET Application of Simple Western to analysis of antibody target affinity and specificity sponsored by Bio-Techne

US biopharma still leads the world in high-risk drug development, but the road from innovation to access has never been harder to predict. Hear from top executives and investors on how they’re navigating what’s next. Join us.

in case you missed it 1. Compass, Transcend and Usona Institute win FDA vouchers to expedite new psychedelics 2. Peer Review Pfizer’s strategy chief Andrew Baum steps down; Helus Pharma swaps out CEO after two months 3. Novartis pulls Pluvicto prostate cancer label expansion filing in the EU 4. Daiichi Sankyo postpones annual results, stock dips 5. Sanofi’s tolebrutinib gets CHMP backing for certain MS patients after FDA rejection 6. Trump ousts National Science Board members